Marshall Financial Group LLC Makes New $304,000 Investment in West Pharmaceutical Services, Inc. (NYSE:WST)

Marshall Financial Group LLC bought a new position in West Pharmaceutical Services, Inc. (NYSE:WST) during the third quarter, according to its most recent Form 13F filing with the SEC. The firm bought 1,013 shares of the medical instruments supplier’s stock, valued at approximately $304,000.

A number of other institutional investors have also bought and sold shares of the business. Findlay Park Partners LLP lifted its stake in West Pharmaceutical Services by 30.6% in the 1st quarter. Findlay Park Partners LLP now owns 597,106 shares of the medical instruments supplier’s stock worth $236,281,000 after purchasing an additional 139,800 shares in the last quarter. Kayne Anderson Rudnick Investment Management LLC lifted its stake in West Pharmaceutical Services by 6.8% in the 2nd quarter. Kayne Anderson Rudnick Investment Management LLC now owns 593,692 shares of the medical instruments supplier’s stock worth $195,556,000 after purchasing an additional 37,702 shares in the last quarter. ProShare Advisors LLC lifted its stake in West Pharmaceutical Services by 13.9% in the 1st quarter. ProShare Advisors LLC now owns 500,662 shares of the medical instruments supplier’s stock worth $198,117,000 after purchasing an additional 61,247 shares in the last quarter. Sei Investments Co. lifted its stake in West Pharmaceutical Services by 12.7% in the 2nd quarter. Sei Investments Co. now owns 401,026 shares of the medical instruments supplier’s stock worth $132,095,000 after purchasing an additional 45,208 shares in the last quarter. Finally, Envestnet Asset Management Inc. lifted its stake in West Pharmaceutical Services by 9.8% in the 2nd quarter. Envestnet Asset Management Inc. now owns 301,339 shares of the medical instruments supplier’s stock worth $99,258,000 after purchasing an additional 26,947 shares in the last quarter. 93.90% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, VP Charles Witherspoon sold 1,029 shares of West Pharmaceutical Services stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $300.00, for a total transaction of $308,700.00. Following the sale, the vice president now owns 1,478 shares of the company’s stock, valued at approximately $443,400. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.53% of the company’s stock.

West Pharmaceutical Services Trading Up 1.6 %

WST opened at $293.32 on Friday. The firm has a market capitalization of $21.37 billion, a price-to-earnings ratio of 38.70, a price-to-earnings-growth ratio of 10.53 and a beta of 1.01. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.34 and a quick ratio of 1.68. The company’s 50 day simple moving average is $299.96 and its two-hundred day simple moving average is $325.39. West Pharmaceutical Services, Inc. has a 1-year low of $265.00 and a 1-year high of $413.70.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings results on Thursday, July 25th. The medical instruments supplier reported $1.52 EPS for the quarter, missing the consensus estimate of $1.74 by ($0.22). The firm had revenue of $702.10 million for the quarter, compared to analysts’ expectations of $729.36 million. West Pharmaceutical Services had a net margin of 18.25% and a return on equity of 19.17%. The firm’s quarterly revenue was down 6.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.11 EPS. Analysts expect that West Pharmaceutical Services, Inc. will post 6.42 EPS for the current fiscal year.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.